Differential modulation of inflammatory cytokines by recombinant IL-10 in IL-1β and TNF-α ̶ stimulated equine chondrocytes and synoviocytes: impact of washing and timing on cytokine responses.
Authors: Elkhenany Hoda A, Linardi Renata L, Ortved Kyla F
Journal: BMC veterinary research
Summary
# Editorial Summary: IL-10 as an Anti-inflammatory Agent for Equine Osteoarthritis Osteoarthritis management in horses demands effective anti-inflammatory interventions, yet translating laboratory findings into clinical success requires in vitro protocols that accurately mirror real-world joint biology. Elkhenany and colleagues investigated whether recombinant IL-10 (rIL-10) could suppress the inflammatory cascade in equine joint cells using two experimental models: one involving cell washing before treatment and one without, with cytokine and protease expression measured over 6–24 hours following IL-1β and TNF-α stimulation. The most promising results emerged from the unwashed model, where rIL-10 at 10–20 ng/mL concentrations substantially reduced expression and secretion of IL-1β, TNF-α, IL-8, MMP-13, and ADAMTS5 after 24 hours—markers directly implicated in cartilage degradation. Notably, rIL-10 effects were highly dependent on treatment timing and whether inflammatory mediators remained present in the cell culture environment, suggesting that clinical efficacy may hinge on delivering IL-10 whilst active joint inflammation persists rather than after inflammatory triggers have been cleared. These findings position rIL-10 as a credible candidate for intra-articular or systemic OA therapy in horses, though practitioners should note that the model's most encouraging anti-inflammatory signature required 24 hours to fully manifest—a timeline worth considering when evaluating expected therapeutic windows in clinical cases.
Read the full abstract on PubMed
Practical Takeaways
- •IL-10 shows promise as an anti-inflammatory therapy for equine osteoarthritis, but in vivo efficacy remains to be demonstrated in clinical trials
- •The timing and context of anti-inflammatory treatment delivery may be critical—therapeutic effect depends on the inflammatory environment present at time of administration
- •Further work is needed to translate these in vitro findings to intra-articular injection protocols, dosing regimens, and clinical outcomes in lame horses
Key Findings
- •Recombinant IL-10 at 10-20 ng/mL significantly reduced expression of IL-1β, TNF-α, IL-8, MMP-13, and ADAMTS5 in both equine chondrocytes and synoviocytes when cells were not washed before treatment
- •IL-10 treatment decreased IL-1β and TNF-α protein content in synoviocyte supernatants after 6-24 hours, with strongest effects at 10-20 ng/mL
- •Washing cells prior to IL-10 treatment substantially reduced therapeutic efficacy, suggesting residual inflammatory stimuli enhance IL-10 responsiveness
- •IL-6 expression showed cell-type dependent responses, increasing in chondrocytes but decreasing in synoviocytes with IL-10 treatment